Quality statement Adults with non-ST-segment-elevation myocardial infarction (NSTEMI) or unstable angina who have an intermediate or higher risk of future adverse cardiovascular events who are having ...

Overview This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment ...

Ensure fondaparinux is offered to patients with unstable angina or non ST-segment elevation myocardial infarction (NSTEMI).1 Fondaparinux has been shown to be clinically superior to enoxaparin in ...

(HealthDay) -- Aspirin is still the first line of therapy for patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and ticagrelor can be used in place of clopidogrel ...

Oral anti-platelet therapy Effient (prasugrel) has been added to the updated clinical practice guidelines as a class I recommended treatment option for patients undergoing Percutaneous Coronary ...

2. Moliterno DJ, Granger CB. Chapter 6. Differencesbetween unstable angina and acute myocardial infarction.In: Topol E, ed. NewYork, NY: Marcel Dekker; 1998:135-172. Circulation. 3.

The market for Unstable Angina Therapeutics is expected to grow to $4.05 billion in FY 2023. According to Future Market Insights, the Unstable Angina Therapeutics market grew at a CAGR of 4% from 2018 ...

The National Institute for Health and Clinical Excellence is hoping new guidelines on the early management of Acute Coronary Syndromes – specifically unstable angina and a specific type of heart ...

Individuals with diabetes and acute coronary syndromes such as a heart attack or unstable angina have an increased risk of death at 30 days and one year after ACS, compared with ACS patients ...

PARSIPPANY, N.J. and INDIANAPOLIS, Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients ...